VIVALIA - Centre Hospitalier de l'Ardenne

The oncology department at VIVALIA - Centre Hospitalier de l'Ardenne is conducting a trial that evaluates a novel immune‑targeting antibody in patients with advanced prostate disease. The study compares the combination therapy against standard chemotherapy to determine its impact on disease control.

• Combination of immunotherapy with chemotherapy
• Assessment of radiographic progression‑free survival
• Focus on treatment‑resistant disease
• Patient‑reported outcomes and safety monitoring

This research aims to improve therapeutic options for men with metastatic castration‑resistant prostate cancer, offering hope for longer disease stabilization.

In the lung cancer program, investigators are testing a new agent against an established checkpoint inhibitor in patients whose tumors express high levels of PD‑L1. The trial measures overall survival and progression‑free survival to gauge the relative benefit of the experimental therapy.

• First‑line immunotherapy for PD‑L1‑high disease
• Comparison of novel agent versus standard pembrolizumab
• Evaluation of overall and progression‑free survival
• Incorporation of biomarker‑driven enrollment

By exploring a different mechanism of immune activation, the study seeks to expand treatment choices for patients with metastatic non‑small cell lung cancer.